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Editorial on the Research Topic
gd T Cells in Cancer
Since the discovery of gd T cells, this rare and unique component of the immune system has been
recognized for its potential in cancer immunology and immunotherapy. In the mid-1980s, it became
clear that a major component of adaptive immune responses is the ability of T cell receptors (TCR)
to undergo somatic recombination in order to recognize multiple antigens. TCRs consisting of
either ab and gd chains were discovered in rapid succession (1–6). An important observation was
made in these initial studies: gd T cells stimulated through their TCR are able to kill cancer cells (2).
Over these past decades, researchers have learned that gd T cells share many similarities with ab T
cells, as well as major differences. However, discoveries in gd T cell biology have failed to keep the
same pace as ab T cell biology. The molecular targets of gdTCRs and functions of these cells have
largely eluded researchers, partly because gd T cell recognition of cancer cells and their response
kinetics are very different to ab T cells (7, 8). Recent years have seen major advances in gd T cell
biology and established the non-redundancy of this lymphocyte subset, particularly in the context of
cancer (9–11). gd T cells are being used as cellular vehicles to target tumors and prognostic
indicators of cancer progression. The aim of the articles collected in this Research Topic is to
describe new developments and approaches to enhance the anti-tumor functions of gd T cells, and
to discuss how expression of their ligands can assist with prognosis of cancer patients.
Given the robust ability of gd T cells to kill cancer cells, various strategies to enhance their
cytotoxic behavior are being pursued in the laboratory. The Vg9Vd2 cell subset in humans
recognizes transformed cells with dysfunctional metabolism, primarily through the up-regulation
of phosphoantigens stemming from abnormalities in the mevalonate pathway. One of the best
studied phosphoantigens is isopentenyl pyrophosphate (IPP), which activates a receptor complex in
cancer cells consisting of butyrophilin (BTN)-3A1 and BTN2A1 (12, 13). However, very little
information exists on how this receptor complex is presented on the cell surface and its other
interacting partners. Laplagne et al. report on the importance of the GTPase, RhoB, in regulating
BTN3A1 presentation on the cell membrane. They observed that the differential susceptibility of
lung tumor cell lines to Vg9Vd2 T-cell killing correlated with differential subcellular and plasma
membrane distribution of RhoB. There are a few methods to increase Vg9Vd2 cell recognition of
cancer cells, primarily via boosting the IPP-activated BTN3A1/BTN2A1 complex. Bisphosphonate
drugs increase accumulation of IPP making cancer cells more susceptible to Vg9Vd2 cell killing, but
these drugs also induce proliferation of Vg9Vd2 cells in culture. Okuno et al. report on a newly
synthesized bisphosphonate drug, pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-org November 2020 | Volume 11 | Article 6024111
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increases their ability to recognize cancer cells.
gd T cells are also being equipped with chimeric antigen
receptors (CAR) for hematological and epithelial-derived
malignancies. Most likely, gd CAR T cells will associate with a
lower risk of cytokine release syndrome as reported for NK CAR
cells. Whether gd CAR T cells will overcome the scarce infiltration
of tumors by classical ab CAR T cells remains to tested and might
depend on the type of gd T cells (i.e. Vd1 cells versus Vd2 cells),
which have naturally different homing tissues. Rozenbaum et al.
describe a new expansion protocol that generates high numbers of
pure (> 99%) gd T cells which could be efficiently transduced with
CAR constructs. CD19-directed gd CAR T cells efficiently killed
CD19+ leukemic cells in vitro and in vivo. To test these various
strategies whose goal is augment gd T cell cytotoxic function, a
variety of pre-clinical models are used that evaluate killing efficacy,
but these models come with their own challenges. Joalland and
Scotet summarize the advantages and disadvantages of the most
commonly used pre-clinical models in gd T cell immunotherapy.
In addition to the use of immunodeficient mice transplanted with
human tumor cells and gd T cells, they also discuss the urgent need
for improved animal-free in vitro models such as spheroids
and organoids.
Another outstanding question in the field is how gd T cell
function may be suppressed by tumors. Siegers et al. show that an
embryonic-associated molecule, called NODAL, expressed by
breast cancer cells, impacts gd T cell function. In human breast
tumors, gd T cells are found in close proximity to NODAL+ cancer
cells. Through gain-of-function and loss-of-function experiments,
the authors report that NODAL expression on breast cancer cell
lines reduces gd T-cell cytotoxicity. Gonnermann et al. describe a
novel immunosuppression pathway in pancreatic cancer, where
Galectin-3 secreted by cancer cells inhibits gd T cell proliferation
via a3b1 integrin. Interestingly, the cytotoxic activity of gd T cells
was not impaired by Galectin-3.
This Research Topic includes two clinical trials. One trial
investigated the ability of b-adrenergic receptor activation to
mobilize gd T cells into the peripheral blood of test subjects.
Baker et al. found that drugs antagonizing the b-adrenergic
receptor pathway not only prevent gd T cell accumulation in
blood, but that this pathway is also important for gd T cell
expansion ex vivo. These data suggest that b-adrenergic receptor
agonists may improve expansion protocols or gd T cell cytotoxic
function. The second clinical trial included 46 children with
acute leukemia that received hematopoietic stem cellFrontiers in Immunology | www.frontiersin.org 2transplantation of abTCR/CD19-depleted haploidentical grafts.
Merli et al. tested the ability of the bisphosphonate drug,
zoledronic acid, to counteract graft-versus-host-disease in these
patients, and they show that zoledronic acid is well tolerated.
Moreover, the children that received more doses of zoledronic
acid had a better outcome than the children receiving
fewer doses.
Finally, two articles in this collection discuss the importance
of gd T cell ligands in cancer immunotherapy. Bartish et al.
summarize the role of immunosuppressive molecules that
contain sugar residues as well as the relationship between these
glyco-molecules and gd T cells, highlighting opportunities for
intervention. Wang et al. wrote a meta-analysis on publications
pertaining to the BTN family. In this review, the authors also
provide prognostic data for several BTN family members in lung
adenocarcinoma and lung squamous cell carcinoma.
Together, this Research Topic features new developments in
gd T cell cancer immunotherapy, providing insight into
mechanisms that both increase and suppress their effector
functions. Finding the right patient population in which to
manipulate these pathways and exploit this new information
may be key to counteracting cancer.AUTHOR CONTRIBUTIONS
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